LUND, SWEDEN – Immunovia AB (publ) advises that the Board of Directors has decided to postpone the Annual General Meeting (AGM) to 7 April 2022 as there is currently no legislative basis to conduct statutory meetings without any physical participation. The AGM was originally scheduled to take place on 15 March 2022.
The Temporary Exemptions to Facilitate the Conduct of Company and Association Meetings Act (Swe: Lagen om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor), also known as the Temporary Meetings Act, came into effect in the spring of 2020 to allow limited liability companies and economic associations to conduct statutory meetings without any physical participation. The law ceased to apply at the start of 2022. On January 20, 2022, the Ministry of Justice proposed that Temporary Meetings Act be reintroduced from 1 March 2022. The proposed reintroduction has not yet passed the Swedish parliament which creates uncertainty around the ability of Immunovia AB to conduct the AGM without any physical participation.
The Notice of Annual General Meeting will be issued no later than four weeks prior to the new date for the AGM.
For more information, please contact:
Senior Director Investor Relations and Corporate Communications
Tel: +46 736 36 35 74
The information was submitted for publication on February 3, 2022, at CET 10:00 a.m.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
Press release (PDF)